Antimicrobial treatment and supportive care
| Treatment . | Granulocyte colony-stimulating factor responsiveness . | P . | ||
|---|---|---|---|---|
| Low . | Medium . | High . | ||
| Intravenous antibiotics, d | ||||
| Incidence, % | 84 | 69 | 60 | .0093 |
| Mean ± SD | 9.4 ± 6.4 | 6.3 ± 6.1 | 4.1 ± 3.9 | |
| Median (range) | 9 (0-28) | 6 (0-25) | 5 (0-18) | < .0001 |
| > 7 days % | 65 | 33 | 14 | < .0001 |
| Intravenous antimycotics, d | ||||
| Incidence, % | 26 | 10 | 12 | .091 |
| Mean ± SD | 2.3 ± 4.7 | 0.5 ± 1.7 | 0.7 ± 2 | |
| Median (range) | 0 (0-20) | 0 (0-7) | 0 (0-9) | .042 |
| Intravenous virustatics, d | ||||
| Incidence, % | 16 | 21 | 10 | .24 |
| Mean ± SD | 1.4 ± 4.1 | 2.0 ± 5.6 | 0.5 ± 1.8 | |
| Median (range) | 0 (0-18) | 0 (0-33) | 0 (0-11) | .16 |
| Red blood cell transfusions, units | ||||
| Mean ± SD | 2.5 ± 2.2 | 2.1 ± 1.8 | 1.8 ± 1.9 | |
| Median (range) | 2 (0-11) | 2 (0-6) | 2 (0-10) | .27 |
| Platelet transfusions, units | ||||
| Mean ± SD | 3.1 ± 2.1 | 2.1 ± 1.5 | 1.4 ± 1.9 | |
| Median (range) | 3 (0-8) | 2 (0-8) | 1 (0-14) | < .0001 |
| Applications of G-CSF from day +5, d | ||||
| Mean ± SD | 7.1 ± 2.7 | 7.6 ± 2.3 | 7.2 ± 1.7 | |
| Median (range) | 7 (0-13) | 7 (0-13) | 7 (0-12) | .52 |
| ≥ 10 days % | 21 | 14 | 8 | .05 |
| Hospitalization from transplantation, d | ||||
| Mean ± SD | 17.0 ± 4.0 | 15.6 ± 3.6 | 14.5 ± 2.5 | |
| Median (range) | 16 (11-27) | 15 (12-28) | 14 (11-26) | .0017 |
| Transplanted CD34+ cells, ×106/kg | ||||
| Mean ± SD | 5.9 ± 4.1 | 4.2 ± 2.3 | 5.2 ± 2.7 | * |
| Median (range) | 5.0 (2.2-22.0) | 3.4 (2.0-12.3) | 4.2 (2.3-14.2) | |
| Treatment . | Granulocyte colony-stimulating factor responsiveness . | P . | ||
|---|---|---|---|---|
| Low . | Medium . | High . | ||
| Intravenous antibiotics, d | ||||
| Incidence, % | 84 | 69 | 60 | .0093 |
| Mean ± SD | 9.4 ± 6.4 | 6.3 ± 6.1 | 4.1 ± 3.9 | |
| Median (range) | 9 (0-28) | 6 (0-25) | 5 (0-18) | < .0001 |
| > 7 days % | 65 | 33 | 14 | < .0001 |
| Intravenous antimycotics, d | ||||
| Incidence, % | 26 | 10 | 12 | .091 |
| Mean ± SD | 2.3 ± 4.7 | 0.5 ± 1.7 | 0.7 ± 2 | |
| Median (range) | 0 (0-20) | 0 (0-7) | 0 (0-9) | .042 |
| Intravenous virustatics, d | ||||
| Incidence, % | 16 | 21 | 10 | .24 |
| Mean ± SD | 1.4 ± 4.1 | 2.0 ± 5.6 | 0.5 ± 1.8 | |
| Median (range) | 0 (0-18) | 0 (0-33) | 0 (0-11) | .16 |
| Red blood cell transfusions, units | ||||
| Mean ± SD | 2.5 ± 2.2 | 2.1 ± 1.8 | 1.8 ± 1.9 | |
| Median (range) | 2 (0-11) | 2 (0-6) | 2 (0-10) | .27 |
| Platelet transfusions, units | ||||
| Mean ± SD | 3.1 ± 2.1 | 2.1 ± 1.5 | 1.4 ± 1.9 | |
| Median (range) | 3 (0-8) | 2 (0-8) | 1 (0-14) | < .0001 |
| Applications of G-CSF from day +5, d | ||||
| Mean ± SD | 7.1 ± 2.7 | 7.6 ± 2.3 | 7.2 ± 1.7 | |
| Median (range) | 7 (0-13) | 7 (0-13) | 7 (0-12) | .52 |
| ≥ 10 days % | 21 | 14 | 8 | .05 |
| Hospitalization from transplantation, d | ||||
| Mean ± SD | 17.0 ± 4.0 | 15.6 ± 3.6 | 14.5 ± 2.5 | |
| Median (range) | 16 (11-27) | 15 (12-28) | 14 (11-26) | .0017 |
| Transplanted CD34+ cells, ×106/kg | ||||
| Mean ± SD | 5.9 ± 4.1 | 4.2 ± 2.3 | 5.2 ± 2.7 | * |
| Median (range) | 5.0 (2.2-22.0) | 3.4 (2.0-12.3) | 4.2 (2.3-14.2) | |
Not an outcome variable.